Jump to content

Piflufolastat (18F): Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
pubchem and question the CAS
title, name
 
(17 intermediate revisions by 8 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{DISPLAYTITLE:Piflufolastat (<sup>18</sup>F)}}
{{Use American English|date=September 2021}}
{{Use American English|date=September 2021}}
{{Use dmy dates|date=September 2021}}
{{Use dmy dates|date=September 2021}}
{{Infobox drug
{{Infobox drug
| drug_name =
| image = Piflufolastat F-18 v01.svg
⚫
| INN =
⚫
| type = <!-- empty -->
| image =
| width =
| width =
| alt =
| alt =
| caption =
| caption =
⚫
| USAN = piflufolastat F18


<!-- Clinical data -->
<!-- Clinical data -->
| pronounce =
| pronounce =
| tradename = Pylarify
| tradename = Pylarify, Pylclari
| Drugs.com =
| Drugs.com = {{drugs.com|cons|piflufolastat-f-18}}
| MedlinePlus =
| MedlinePlus =
| licence_EU = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID = Piflufolastat
| DailyMedID = Piflufolastat
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_AU_comment =
| pregnancy_AU_comment =
| pregnancy_category=
| pregnancy_category=
| routes_of_administration = [[Intravenous]]
| routes_of_administration = [[Intravenous]]
| class =
| class =
| ATCvet =
| ATC_prefix = V09
| ATC_prefix = None
| ATC_suffix = IX16
| ATC_suffix =
| ATC_supplemental =
| ATC_supplemental =


Line 42: Line 38:
| legal_UK_comment =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US = Rx-only
| legal_US_comment = <ref name="Pylarify FDA label">{{cite web | title=Pylarify- piflufolastat f-18 injection | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553 | access-date=12 September 2021}}</ref>
| legal_US_comment = <ref name="Pylarify FDA label">{{cite web | title=Pylarify- piflufolastat f-18 injection | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553 | access-date=12 September 2021 | archive-date=13 September 2021 | archive-url=https://web.archive.org/web/20210913045312/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a00e5cbc-4fd5-4280-82ec-cd3498df4553 | url-status=live }}</ref>
| legal_EU =
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Pylclari EPAR">{{cite web | title=Pylclari EPAR | website=European Medicines Agency | date=28 July 2023 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/pylclari | access-date=4 August 2023}}</ref><ref>{{cite web | title=Pylclari | website=Union Register of medicinal products | date=25 July 2023 | url=https://ec.europa.eu/health/documents/community-register/html/h1746.htm | access-date=4 August 2023}}</ref>
| legal_EU_comment =
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV -->
| legal_UN_comment =
| legal_UN_comment =
Line 60: Line 56:


<!-- Identifiers -->
<!-- Identifiers -->
| CAS_number_Ref =
| CAS_number = 1207181-29-0
| CAS_number = 1423758-00-2 <!--or is it 1207181-29-0 for this particular isotope of F? -->
| CAS_supplemental =
| CAS_supplemental =
⚫
| CAS_number2 =
| PubChem = 52950901
| PubChem = 52950901
| IUPHAR_ligand =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank = DB14805
| DrugBank = DB14805
| ChemSpiderID_Ref =
| ChemSpiderID = 32702072
| ChemSpiderID = 32702072
| UNII_Ref =
| UNII = 3934EF02T7
| UNII = 3934EF02T7
| KEGG_Ref =
| KEGG = D12132
| KEGG = D12132
| ChEBI_Ref =
| ChEBI =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL = 4297334
| ChEMBL = 4297334
| NIAID_ChemDB =
| NIAID_ChemDB =
Line 84: Line 74:
| IUPAC_name =
| IUPAC_name =
| chemical_formula = C<sub>18</sub>H<sub>23</sub>[<sup>18</sup>F]N<sub>4</sub>O<sub>8</sub>
| chemical_formula = C<sub>18</sub>H<sub>23</sub>[<sup>18</sup>F]N<sub>4</sub>O<sub>8</sub>
| molecular_weight = 441.4 g/mol
| molecular_weight = 441.4
| molecular_weight_comment = g/mol
| SMILES = OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O
| SMILES = OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O
| StdInChI = 1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
| StdInChI = 1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
Line 101: Line 92:
}}
}}


'''Piflufolastat F-18''', sold under the brand name '''Pylarify''', is a [[PET radiotracer|radioactive diagnostic agent]] used for [[positron emission tomography]] (PET) [[medical imaging|imaging]].<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" /> It is given by intravenous injection.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" />
'''Piflufolastat (<sup>18</sup>F)''', sold under the brand name '''Pylarify''' among others, is a [[PET radiotracer|radioactive diagnostic agent]] used for [[positron emission tomography]] (PET) [[medical imaging|imaging]].<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" /><ref name="pmid34292532">{{cite journal | vauthors = Keam SJ | title = Piflufolastat F 18: Diagnostic First Approval | journal = Molecular Diagnosis & Therapy | volume = 25 | issue = 5 | pages = 647–656 | date = September 2021 | pmid = 34292532 | doi = 10.1007/s40291-021-00548-0 | s2cid = 236174886 }}</ref> It is given by intravenous injection.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" />


The most common adverse reactions include headache, altered taste, and fatigue.<ref name="FDA Pylarify" />
The most common adverse reactions include headache, altered taste, and fatigue.<ref name="FDA Pylarify" />


Piflufolastat F-18 was approved for medical use in the United States in May 2021.<ref name="Pylarify FDA label" /><ref>{{cite web | title=Drug Approval Package: Pylarify | website=U.S. [[Food and Drug Administration]] (FDA) | date=9 June 2021 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000TOC.cfm | access-date=12 September 2021}}</ref><ref name="FDA Pylarify" /> It is the second PSMA-targeted PET imaging drug approved by the U.S. [[Food and Drug Administration]] (FDA).<ref name="FDA Pylarify" /> The first approved PSMA-targeted PET imaging drug is [[Ga 68 PSMA-11]].<ref name="FDA Pylarify" />
Piflufolastat (<sup>18</sup>F) was approved for medical use in the United States in May 2021.<ref name="Pylarify FDA label" /><ref>{{cite web | title=Drug Approval Package: Pylarify | website=U.S. [[Food and Drug Administration]] (FDA) | date=9 June 2021 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000TOC.cfm | access-date=12 September 2021 | archive-date=13 September 2021 | archive-url=https://web.archive.org/web/20210913045312/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214793Orig1s000TOC.cfm | url-status=live }}</ref><ref name="FDA Pylarify" /> It is the second PSMA-targeted PET imaging drug approved by the U.S. [[Food and Drug Administration]] (FDA).<ref name="FDA Pylarify" /> The first approved PSMA-targeted PET imaging drug is [[Ga 68 PSMA-11]].<ref name="FDA Pylarify" />


== Medical uses ==
== Medical uses ==
Piflufolastat F-18 is [[Indication (medicine)|indicated]] for people with suspected prostate cancer metastasis (when cancer cells spread from the place where they first formed to another part of the body) who are potentially curable by surgery or other therapy.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" /> Piflufolastat F-18 is also indicated for people with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify">{{cite web | title=FDA approves PSMA-targeted imaging drug for men with prostate cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=27 May 2021 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer | access-date=12 September 2021}} {{PD-notice}}</ref>
Piflufolastat (<sup>18</sup>F) is [[Indication (medicine)|indicated]] for people with suspected prostate cancer metastasis (when cancer cells spread from the place where they first formed to another part of the body) who are potentially curable by surgery or other therapy.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify" /> Piflufolastat (<sup>18</sup>F) is also indicated for people with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.<ref name="Pylarify FDA label" /><ref name="FDA Pylarify">{{cite web | title=FDA approves PSMA-targeted imaging drug for men with prostate cancer | website=U.S. [[Food and Drug Administration]] (FDA) | date=27 May 2021 | url=https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer | access-date=12 September 2021 | archive-date=11 September 2021 | archive-url=https://web.archive.org/web/20210911111447/https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer | url-status=live }} {{PD-notice}}</ref>


== History ==
== History ==
The safety and efficacy of piflufolastat F-18 were evaluated in two prospective clinical trials with a total of 593 men with prostate cancer who each received one injection of piflufolastat F-18.<ref name="FDA Pylarify" /> In the first trial, a cohort of 268 participants with biopsy-proven prostate cancer underwent PET/CT scans performed with piflufolastat F-18.<ref name="FDA Pylarify" /> These participants were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis.<ref name="FDA Pylarify" /> Among the participants who proceeded to surgery, those with positive readings in the pelvic lymph nodes on piflufolastat F-18 PET had a clinically important rate of metastatic cancer confirmed by surgical pathology.<ref name="FDA Pylarify" />
The safety and efficacy of piflufolastat (<sup>18</sup>F) were evaluated in two prospective clinical trials (trial 1/NCT02981368 and trial 2/NCT03739684) with a total of 593 men with prostate cancer who each received one injection of piflufolastat (<sup>18</sup>F).<ref name="FDA Pylarify" /><ref name="Pylarify FDA snapshot">{{cite web | title=Drug Trials Snapshots: Pylarify | website=U.S. Food and Drug Administration | date=26 May 2021 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pylarify | access-date=28 July 2023 | archive-date=28 July 2023 | archive-url=https://web.archive.org/web/20230728202517/https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pylarify | url-status=live }} {{PD-notice}}</ref> In the first trial, a cohort of 268 participants with biopsy-proven prostate cancer underwent PET/CT scans performed with piflufolastat (<sup>18</sup>F).<ref name="FDA Pylarify" /> These participants were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis.<ref name="FDA Pylarify" /> Among the participants who proceeded to surgery, those with positive readings in the pelvic lymph nodes on piflufolastat (<sup>18</sup>F) PET had a clinically important rate of metastatic cancer confirmed by surgical pathology.<ref name="FDA Pylarify" />


The second trial enrolled 208 participants who had rising serum PSA levels after initial prostate surgery or other definitive therapy, and thus had biochemical evidence of recurrent prostate cancer.<ref name="FDA Pylarify" /> Prior to a single piflufolastat F-18 PET/CT scan, all of these participants had baseline conventional imaging performed that did not show definite spread of prostate cancer.<ref name="FDA Pylarify" /> Piflufolastat F-18 PET detected at least one positive lesion in at least one body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of these participants.<ref name="FDA Pylarify" /> In participants with positive piflufolastat F-18 PET readings who had correlative tissue pathology from biopsies, results from baseline or follow-up imaging by conventional methods, or serial PSA levels available for comparison, local recurrence or metastasis of prostate cancer was confirmed in an estimated 85% to 87% of cases, depending on the reader.<ref name="FDA Pylarify" /> Thus, the second trial demonstrated that piflufolastat F-18 PET can detect sites of disease in participants with biochemical evidence of recurrent prostate cancer, thereby providing important information that may impact the approach to therapy.<ref name="FDA Pylarify" />
The second trial enrolled 208 participants who had rising serum prostate-specific antigen levels after initial prostate surgery or other definitive therapy, and thus had biochemical evidence of recurrent prostate cancer.<ref name="FDA Pylarify" /> Prior to a single piflufolastat (<sup>18</sup>F) PET/CT scan, all of these participants had baseline conventional imaging performed that did not show definite spread of prostate cancer.<ref name="FDA Pylarify" /> Piflufolastat (<sup>18</sup>F) PET detected at least one positive lesion in at least one body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of these participants.<ref name="FDA Pylarify" /> In participants with positive piflufolastat (<sup>18</sup>F) PET readings who had correlative tissue pathology from biopsies, results from baseline or follow-up imaging by conventional methods, or serial PSA levels available for comparison, local recurrence or metastasis of prostate cancer was confirmed in an estimated 85% to 87% of cases, depending on the reader.<ref name="FDA Pylarify" /> Thus, the second trial demonstrated that piflufolastat (<sup>18</sup>F) PET can detect sites of disease in participants with biochemical evidence of recurrent prostate cancer, thereby providing important information that may impact the approach to therapy.<ref name="FDA Pylarify" />


Trial 1 included two groups of participants, some with recently diagnosed prostate cancer and others with suspicious findings on standard tests.<ref name="Pylarify FDA snapshot" /> Trial 2 included participants who were treated for prostate cancer before, but there was suspicion that the cancer was spreading because of rising prostate-specific antigen.<ref name="Pylarify FDA snapshot" /> Participants in trial 2 and the recently diagnosed participants in trial 1 were studied for effectiveness of piflufolastat (<sup>18</sup>F), and all participants were studied for safety.<ref name="Pylarify FDA snapshot" /> Trial 1 was conducted at eight sites in the United States and two sites in Canada, and trial 2 was conducted at thirteen sites in the United States and one site in Canada.<ref name="Pylarify FDA snapshot" /> The number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety.<ref name="Pylarify FDA snapshot" />
⚫
The U.S. [[Food and Drug Administration]] (FDA) granted approval of Pylarify to Progenics Pharmaceuticals, Inc.<ref name="FDA Pylarify" />

⚫
The US [[Food and Drug Administration]] (FDA) granted approval of Pylarify to Progenics Pharmaceuticals, Inc.<ref name="FDA Pylarify" />


== References ==
== References ==
Line 122: Line 115:


== External links ==
== External links ==
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/1207181-29-0 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Piflufolastat F18 }}
* {{cite web | url=https://www.lantheus.com//assets/PYLARIFY-piflufolastat-F18-injection-SDS-V2.1-5.29.2021.pdf | title=SDS Data Sheet }}
* {{cite web | url=https://www.lantheus.com//assets/PYLARIFY-piflufolastat-F18-injection-SDS-V2.1-5.29.2021.pdf | title=SDS Data Sheet }}
* {{ClinicalTrialsGov|NCT02981368|Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)}}
* {{ClinicalTrialsGov|NCT02981368|Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer (OSPREY)}}
Line 131: Line 123:
{{Portal bar | Medicine}}
{{Portal bar | Medicine}}


{{DEFAULTSORT:Piflufolastat F-18}}
{{DEFAULTSORT:Piflufolastat 18F}}
[[Category:Medicinal radiochemistry]]
[[Category:Medicinal radiochemistry]]
[[Category:PET radiotracers]]
[[Category:PET radiotracers]]
[[Category:Radiopharmaceuticals]]
[[Category:Radiopharmaceuticals]]


{{Pharma-stub}}

Latest revision as of 04:22, 24 December 2024

Piflufolastat (18F)
Clinical data
Trade namesPylarify, Pylclari
Other names18F-DCFPyL, piflufolastat F18 (USAN US)
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H23[18F]N4O8
Molar mass441.4 g/mol
3D model (JSmol)
  • OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)C1=CC=C([18F])N=C1)C(O)=O)C(O)=O
  • InChI=1S/C18H23FN4O8/c19-13-6-4-10(9-21-13)15(26)20-8-2-1-3-11(16(27)28)22-18(31)23-12(17(29)30)5-7-14(24)25/h4,6,9,11-12H,1-3,5,7-8H2,(H,20,26)(H,24,25)(H,27,28)(H,29,30)(H2,22,23,31)/t11-,12-/m0/s1/i19-1
  • Key:OLWVRJUNLXQDSP-MVBOSPHXSA-N

Piflufolastat (18F), sold under the brand name Pylarify among others, is a radioactive diagnostic agent used for positron emission tomography (PET) imaging.[1][4][5] It is given by intravenous injection.[1][4]

The most common adverse reactions include headache, altered taste, and fatigue.[4]

Piflufolastat (18F) was approved for medical use in the United States in May 2021.[1][6][4] It is the second PSMA-targeted PET imaging drug approved by the U.S. Food and Drug Administration (FDA).[4] The first approved PSMA-targeted PET imaging drug is Ga 68 PSMA-11.[4]

Medical uses

[edit]

Piflufolastat (18F) is indicated for people with suspected prostate cancer metastasis (when cancer cells spread from the place where they first formed to another part of the body) who are potentially curable by surgery or other therapy.[1][4] Piflufolastat (18F) is also indicated for people with suspected prostate cancer recurrence based on elevated serum prostate-specific antigen (PSA) levels.[1][4]

History

[edit]

The safety and efficacy of piflufolastat (18F) were evaluated in two prospective clinical trials (trial 1/NCT02981368 and trial 2/NCT03739684) with a total of 593 men with prostate cancer who each received one injection of piflufolastat (18F).[4][7] In the first trial, a cohort of 268 participants with biopsy-proven prostate cancer underwent PET/CT scans performed with piflufolastat (18F).[4] These participants were candidates for surgical removal of the prostate gland and pelvic lymph nodes and were considered at higher risk for metastasis.[4] Among the participants who proceeded to surgery, those with positive readings in the pelvic lymph nodes on piflufolastat (18F) PET had a clinically important rate of metastatic cancer confirmed by surgical pathology.[4]

The second trial enrolled 208 participants who had rising serum prostate-specific antigen levels after initial prostate surgery or other definitive therapy, and thus had biochemical evidence of recurrent prostate cancer.[4] Prior to a single piflufolastat (18F) PET/CT scan, all of these participants had baseline conventional imaging performed that did not show definite spread of prostate cancer.[4] Piflufolastat (18F) PET detected at least one positive lesion in at least one body region (bone, prostate bed, pelvic lymph node, other lymph nodes, or soft tissue) in 60% of these participants.[4] In participants with positive piflufolastat (18F) PET readings who had correlative tissue pathology from biopsies, results from baseline or follow-up imaging by conventional methods, or serial PSA levels available for comparison, local recurrence or metastasis of prostate cancer was confirmed in an estimated 85% to 87% of cases, depending on the reader.[4] Thus, the second trial demonstrated that piflufolastat (18F) PET can detect sites of disease in participants with biochemical evidence of recurrent prostate cancer, thereby providing important information that may impact the approach to therapy.[4]

Trial 1 included two groups of participants, some with recently diagnosed prostate cancer and others with suspicious findings on standard tests.[7] Trial 2 included participants who were treated for prostate cancer before, but there was suspicion that the cancer was spreading because of rising prostate-specific antigen.[7] Participants in trial 2 and the recently diagnosed participants in trial 1 were studied for effectiveness of piflufolastat (18F), and all participants were studied for safety.[7] Trial 1 was conducted at eight sites in the United States and two sites in Canada, and trial 2 was conducted at thirteen sites in the United States and one site in Canada.[7] The number of participants representing efficacy findings may differ from the number of participants representing safety findings due to different pools of study participants analyzed for efficacy and safety.[7]

The US Food and Drug Administration (FDA) granted approval of Pylarify to Progenics Pharmaceuticals, Inc.[4]

References

[edit]
  1. ^ a b c d e f "Pylarify- piflufolastat f-18 injection". DailyMed. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
  2. ^ "Pylclari EPAR". European Medicines Agency. 28 July 2023. Retrieved 4 August 2023.
  3. ^ "Pylclari". Union Register of medicinal products. 25 July 2023. Retrieved 4 August 2023.
  4. ^ a b c d e f g h i j k l m n o p q r "FDA approves PSMA-targeted imaging drug for men with prostate cancer". U.S. Food and Drug Administration (FDA). 27 May 2021. Archived from the original on 11 September 2021. Retrieved 12 September 2021. Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ Keam SJ (September 2021). "Piflufolastat F 18: Diagnostic First Approval". Molecular Diagnosis & Therapy. 25 (5): 647–656. doi:10.1007/s40291-021-00548-0. PMID 34292532. S2CID 236174886.
  6. ^ "Drug Approval Package: Pylarify". U.S. Food and Drug Administration (FDA). 9 June 2021. Archived from the original on 13 September 2021. Retrieved 12 September 2021.
  7. ^ a b c d e f "Drug Trials Snapshots: Pylarify". U.S. Food and Drug Administration. 26 May 2021. Archived from the original on 28 July 2023. Retrieved 28 July 2023. Public Domain This article incorporates text from this source, which is in the public domain.

Public Domain This article incorporates public domain material from the United States Department of Health and Human Services

[edit]
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Piflufolastat_(18F)&oldid=1264913510"